[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0458551T3 - Spiro-isoquinolin-pyrrolidiner og analoge deraf, som er anvendelige som aldosereduktase-inhibitorer. - Google Patents

Spiro-isoquinolin-pyrrolidiner og analoge deraf, som er anvendelige som aldosereduktase-inhibitorer.

Info

Publication number
DK0458551T3
DK0458551T3 DK91304487T DK91304487T DK0458551T3 DK 0458551 T3 DK0458551 T3 DK 0458551T3 DK 91304487 T DK91304487 T DK 91304487T DK 91304487 T DK91304487 T DK 91304487T DK 0458551 T3 DK0458551 T3 DK 0458551T3
Authority
DK
Denmark
Prior art keywords
carbon atoms
aryl
lower alkyl
pyrrolidines
isoquinoline
Prior art date
Application number
DK91304487T
Other languages
English (en)
Inventor
Michael Sotirios Malamas
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of DK0458551T3 publication Critical patent/DK0458551T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK91304487T 1990-05-21 1991-05-17 Spiro-isoquinolin-pyrrolidiner og analoge deraf, som er anvendelige som aldosereduktase-inhibitorer. DK0458551T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/526,356 US5037831A (en) 1990-05-21 1990-05-21 Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors

Publications (1)

Publication Number Publication Date
DK0458551T3 true DK0458551T3 (da) 1998-08-10

Family

ID=24097007

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91304487T DK0458551T3 (da) 1990-05-21 1991-05-17 Spiro-isoquinolin-pyrrolidiner og analoge deraf, som er anvendelige som aldosereduktase-inhibitorer.

Country Status (11)

Country Link
US (1) US5037831A (da)
EP (1) EP0458551B1 (da)
JP (1) JP3244283B2 (da)
AT (1) ATE160780T1 (da)
CA (1) CA2042113C (da)
DE (1) DE69128302T2 (da)
DK (1) DK0458551T3 (da)
ES (1) ES2110977T3 (da)
GR (1) GR3026186T3 (da)
HK (1) HK1004067A1 (da)
SG (1) SG47773A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106978A (en) * 1991-05-22 1992-04-21 American Home Products Corporation Process and intermediates for the preparation of spiro(isoquinoline-4(1H), 3'-pyrrolidine)-1,2', 3,5'(2H)-tetrones which are useful as aldose reductase inhibitors
ES2101291T3 (es) * 1991-11-25 1997-07-01 American Home Prod 1'-amino-2-((benzotiazolil)metil)espiro(isoquinolina-4(1h),3'-pirrolidina)-1,2',3,5'(2h)-tetronas y sus analogos utiles como inhibidores de aldosa reductasa.
US5189167A (en) * 1991-11-25 1993-02-23 American Home Products Corporation Alkylidene analogs of 1'-amino-2-[(benzothiazolyl)-methyl]spiro [isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones useful as aldose reductase inhibitors
US5189168A (en) * 1991-11-25 1993-02-23 American Home Products Corporation 1'-amino-2[(benzothiazolyl)methyl]spiro-[isoquinoline-4(1H),3'-pyrrolidine]-1,2'3,5'(2H)-tetrones and analogs thereof useful as aldose reductase inhibitors
US5189044A (en) * 1992-03-20 1993-02-23 American Home Products Corporation Isoquinoline-1,3-dione acetyl carbamates useful as aldose reductase inhibitors
CN100378118C (zh) * 1997-04-15 2008-04-02 Csir公司 具有食欲抑制剂活性的药物组合物
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
AU2002215160A1 (en) 2000-11-30 2002-06-11 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
EP2368560A1 (en) 2007-03-12 2011-09-28 Zadec ApS An anti-diabetic extract of rooibos
EP2848252A3 (en) 2007-03-23 2015-06-17 The Board of Regents of the University of Texas System Aldose reductase inhibitors for use in treating uveitis
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
AU2011348074B2 (en) 2010-12-23 2016-04-28 The Board Of Regents Of The University Of Texas System Methods for treating COPD
CN107286092B (zh) * 2017-05-24 2020-02-21 浙江大学 甲氧基苯甲酰胺和重氮酸酯经碳-氢官能化制备异喹啉二酮的方法
WO2019165195A1 (en) 2018-02-22 2019-08-29 Srivastava Satish Combination therapy for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
WO1986002647A1 (en) * 1984-10-30 1986-05-09 Pfizer Inc. Spiro-heteroazolones for treatment of diabetes complications
IL80475A (en) * 1985-11-07 1993-01-31 Pfizer Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them
DE3769066D1 (de) * 1986-08-28 1991-05-08 Sanwa Kagaku Kenkyusho Co Hydantoin-derivate zur behandlung von komplikationen bei diabetes.
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
AU617541B2 (en) * 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors

Also Published As

Publication number Publication date
CA2042113A1 (en) 1991-11-22
JPH04226984A (ja) 1992-08-17
DE69128302D1 (de) 1998-01-15
ATE160780T1 (de) 1997-12-15
ES2110977T3 (es) 1998-03-01
HK1004067A1 (en) 1998-11-13
DE69128302T2 (de) 1998-03-26
GR3026186T3 (en) 1998-05-29
EP0458551A1 (en) 1991-11-27
CA2042113C (en) 2001-08-28
US5037831A (en) 1991-08-06
EP0458551B1 (en) 1997-12-03
JP3244283B2 (ja) 2002-01-07
SG47773A1 (en) 1998-04-17

Similar Documents

Publication Publication Date Title
DK0458551T3 (da) Spiro-isoquinolin-pyrrolidiner og analoge deraf, som er anvendelige som aldosereduktase-inhibitorer.
IL103825A0 (en) Aromatic amino-alcohol derivatives,a method for the preparation thereof and pharmaceutical compositions containing the same
FI893467A0 (fi) Menetelmä lääkeaineena käyttökelpoisten 4-oksokinoliini-3-karboksyylihapon johdannaisten valmistamiseksi
AU1039688A (en) 3(2h)pyridazinone, process for its preparation and antagonistic agent against srs-a containing it
DK0430201T3 (da)
CA2030732A1 (fr) Nouveaux derives du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant
CA2042112A1 (en) N'-alkyl-spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
DK0410305T3 (da) Anvendelse af bis(4-hydroxyphenylthio)methanderivater til behandling af diabetes mellitus
ES8606295A1 (es) Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas.
NO914192L (no) 8-azabicyklo(3.2.1)oktylalkylthiazolidinoner, fremgangsmaate for fremstilling og anvendelse som medikamenter
KR930702346A (ko) 알도스 리덕타제 억제제로서 유용한 1'-아미노스피로[이소퀴놀린-4(1h),3'-피롤리딘]-1,2',3,5'(2h)-테트론 및 이의 동족체
DK0410343T3 (da) Anvendelse af bisphenolderivater til behandling af diabetes mellitus
HK108997A (en) 1'-amino-2-(benzothiazolyl)methyl¾spiro isoquinoline-4(1H),3'-pyrrolidine¾-1,2',3,5'(2H)-tetrones and analogs thereof useful as aldose reductase inhibitors
UA81596C2 (en) Nitro-sulfobenzamides
ATE87301T1 (de) N-acyl-n-naphthoylglycine als aldose-reductaseinhibitoren.
ES2032413T3 (es) Procedimiento para preparar pirimidoquinoxalinas sustituidas. (reserva del art. 167.2 cpe).